Stocks · Health care · Pharmaceutical Preparations

NewcelX Ltd.

NCEL Clue Score60
Switzerland Fiscal year ends December CIK 0001783036
$3.05 -2.09% Close, 9 Oct 2026
Price $3.05 +23.78% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 29 Jan 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2018Operating income−3.4Net income−5.1Fiscal year 2019Operating income−4.2Net income−5.4Fiscal year 2020Operating income−2.3Net income−2.9EPS, diluted−0.41Fiscal year 2021Operating income−11.9Net income−11.9EPS, diluted−1.00Fiscal year 2022Operating income−15.5Net income−16.5EPS, diluted−33.52Fiscal year 2023Operating income−3.0Net income−3.3EPS, diluted1.13Fiscal year 2024Operating income−2.1Net income−7.2EPS, diluted2.43Fiscal year 2025Operating income−2.6Net income−8.3EPS, diluted2.16
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income −3.4 −4.2 −2.3 −11.9 −15.5 −3.0 −2.1 −2.6
Net income −5.1 −5.4 −2.9 −11.9 −16.5 −3.3 −7.2 −8.3
Growth
EPS, diluted n/a n/a −0.41 −1.00 −33.52 1.13 2.43 2.16

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2018Operating cash flow−2.7Fiscal year 2019Operating cash flow−0.2Fiscal year 2020Operating cash flow−0.7Fiscal year 2021Operating cash flow−14.9Capital expenditure−0.0Free cash flow−15.0Fiscal year 2022Operating cash flow−13.9Fiscal year 2023Operating cash flow−3.4Capital expenditure−0.0Free cash flow−3.5Fiscal year 2024Operating cash flow−1.1Capital expenditure−0.0Free cash flow−1.1Fiscal year 2025Operating cash flow−2.8Capital expenditure−0.0Free cash flow−2.8
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −2.7 −0.2 −0.7 −14.9 −13.9 −3.4 −1.1 −2.8
Capital expenditure n/a n/a n/a −0.0 n/a −0.0 −0.0 −0.0
Free cash flow n/a n/a n/a −15.0 n/a −3.5 −1.1 −2.8
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2018Cash0.0Shareholders’ equity−8.8Fiscal year 2019Cash0.2Shareholders’ equity−6.2Fiscal year 2020Cash0.1Total debt0.1Net cash (debt)−0.0Shareholders’ equity−9.0Fiscal year 2021Cash5.4Shareholders’ equity0.5Fiscal year 2022Cash8.9Shareholders’ equity0.1Fiscal year 2023Cash1.1Shareholders’ equity−1.2Fiscal year 2024Cash0.7Shareholders’ equity−8.0Fiscal year 2025Cash2.2Shareholders’ equity7.3
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 0.0 0.2 0.1 5.4 8.9 1.1 0.7 2.2
Total debt n/a n/a 0.1 n/a n/a n/a n/a n/a
Net cash (debt) n/a n/a −0.0 n/a n/a n/a n/a n/a
Shareholders’ equity −8.8 −6.2 −9.0 0.5 0.1 −1.2 −8.0 7.3

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021† 31 Dec 2021 FY2022† 31 Dec 2022 FY2023† 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
−2.7 −0.2 −0.7 −14.9 −13.9 −3.4 −1.1 −2.8
Growth
Investment
n/a n/a n/a −0.0 n/a −0.0 −0.0 −0.0
calc n/a n/a n/a −15.0 n/a −3.5 −1.1 −2.8
Growth
calc n/a n/a n/a −1.26 n/a −1.17 −0.36 −0.72
n/a n/a n/a −0.0 n/a 0.1 −0.0 1.7
Financing
0.6 0.4 0.5 20.3 17.4 2.8 0.5 2.6

† The diluted share count jumps at 2021 and 2022 and 2023, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Lines marked calc are worked out here from filed figures; point at one for how. Capital expenditure, dividends and buybacks are shown as money out, so negative.